Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

Amifostine in Treating Patients With Stage II or Stage III Non-small Cell Lung Cancer


A Phase III Randomized Study of Amifostine Mucosal Protection for Patients With Favorable Performance Inoperable Stage II-III A/B Non-Small Cell Lung Cancer (NSCLC) Receiving Sequential Induction and Concurrent Hyperfractionated Radiotherapy With Paclitaxel and Carboplatin


Amifostine may be an effective treatment for the toxic side effects caused by radiation therapy and chemotherapy. It is not yet known whether chemotherapy and radiation therapy are more effective with or without amifostine for non-small cell lung cancer.


Randomized phase III trial to determine the effectiveness of amifostine in treating patients who have stage II or stage III non-small cell lung cancer that cannot be surgically removed and who are undergoing chemotherapy and radiation therapy.

Study Status: Active, not recruiting


Condition Intervention Phase
Drug/Agent Toxicity by Tissue/Organ
Lung Cancer
Oral Complications
Radiation Toxicity
Biological: filgrastim
Drug: amifostine trihydrate
Drug: carboplatin
Drug: paclitaxel
Radiation: radiation therapy
Phase 3

Verified by Radiation Therapy Oncology Group November, 2013

Sponsored by: Radiation Therapy Oncology Group
Information provided by: Radiation Therapy Oncology Group identifier: NCT00003313

Study Type: Interventional

Study Design: Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care

Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio 44195
United States

Benjamin Movsas, MD., Study Chair

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit
  Information obtained from on
Link to the current record.

Cleveland Clinic Mobile Site